Mirna Therapeutics said this week that it has published data in Molecular Therapy showing that a neutral lipid emulsion can be used to systemically deliver tumor-suppressing microRNA mimics and reduce tumor burden in mouse lungs.
In the paper, researchers from Mirna and Yale University used a transgenic mouse model of lung cancer to show that intravenous administration of the lipid-formulated mimics of miR-34 and let-7 triggered an RNAi response in cancer cells and inhibited tumor growth.
“The successful therapeutic delivery of our miRNA mimics in a clinically relevant tumor model is an important milestone in bringing therapeutic miRNAs to the clinic,” Mirna President and CEO Paul Lammers said in a statement. “These data add to the increasing body of evidence that our technology can be applied in a therapeutic context.”